EHEinar August Høgestøl

Einar August Høgestøl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Einar August Høgestøl has a total of 473 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Therapy Choices and Outcomes in Newly Diagnosed Multiple Sclerosis

    by Paula Uibel, Francesca Trogu, Martina Flaskamp, Russell Ouellette, Christiane Gasperi, Ana-Katharina Klein, Mark Mühlau, Daniel Frey, Alexandra Gyllenberg, Einar August Høgestøl, et al.

    Background and ObjectivesProspective multinational studies integrating imaging and soluble biomarkers in early multiple sclerosis (MS) are limited. The MultipleMS study compared 2-year clinical, ra...


  • Open Access

    Normative Modeling of Brain Volume in Multiple Sclerosis Using Healthy Controls

    by Max Korbmacher, Ingrid Anne Lie, Kristin Wesnes, Eric Westman, Thomas Espeseth, Ole A. Andreassen, Lars T. Westlye, Stig Wergeland, Hanne F. Harbo, Gro Owren Nygaard, et al.

    Background and ObjectivesInterpretation of brain atrophy in multiple sclerosis (MS) relies on group-level research and lacks individualized reference standards. Normative modelling can enable patie...

  • Open Access

    Improved visualization and segmentation of the choroid plexus using double inversion recovery MRI

    by Markus Lauerer, Julian McGinnis, Cornelius Berberich, Tun Wiltgen, Einar August Høgestøl, Pål Berg-Hansen, Jan S Kirschke, Bernhard Hemmer, Mark Mühlau

    Background: Choroid plexus (CP) volume is an emerging magnetic resonance imaging (MRI) biomarker in various disorders of the central nervous system (CNS). However, clinical translation is hindered by methodological heterogeneity and inconsistent anatomical coverage. Double inversion recovery (DIR) – a sequence providing dual-tissue suppression – is a promising candidate to improve CP segmentation. Methods: The dataset included 93 scans across healthy subjects and individuals with multiple sclerosis (MS), divided into a training set ( n = 63), an internal test set ( n = 20), and an external test set ( n = 10). First, relative CP signal intensity and tissue contrast ratios on DIR were compared against fluid-attenuated inversion recovery (FLAIR) and T1-weighted (T1w) sequences (pre- and post-contrast). Reproducibility of manual CP segmentations was assessed via intraclass correlation coefficients (ICCs). Subsequently, we developed a 3D nnU-Net model for CP segmentation based on manually labeled DIR masks. Model performance was evaluated against manual segmentation using spatial overlap and volumetric error metrics. Finally, we compared our DIR-based model against three publicly available T1w- or FLAIR-based tools by assessing slice-wise volume distributions and voxel-wise density maps. Results: DIR demonstrated the highest CP signal intensity and most consistent tissue contrast among evaluated MRI sequences ( p < 0.001). Intra- and inter-rater agreement for manual CP segmentations was robust (ICC = 0.92 and 0.83, respectively). The trained nnU-Net achieved high internal accuracy (Dice = 0.82) independent of scanner, diagnosis, or absolute CP volume, and generalized well to the external test set (Dice = 0.75). Compared to public T1w- and FLAIR-based models, DIR-based approaches (nnU-Net and manual) yielded significantly larger CP volumes ( p < 0.01). Axial volume distribution analysis attributed this difference to a distinct bimodal profile in DIR segmentations, more fully capturing the CP inside the temporal horn of the lateral ventricle ( p < 0.001 against T1w- and FLAIR-based models). Conclusions: By leveraging the superior tissue contrast of DIR, our nnU-Net model achieves highly accurate CP segmentation that generalizes across scanners and captures the inferior extent of the C-shaped structure often missed by conventional models. This may improve standardization of CP volumetry and allow for more reliable studies in CNS disorders.

  • Open Access

    Thalamic nuclei volumes across psychiatric and neurological disorders: a multi-site magnetic resonance imaging study

    by V. Mäki-Marttunen, S. Nerland, K. N. Jørgensen, E. A. Høgestøl, J. Rokicki, D. Alnæs, S. Borgwardt, B. Boye, J. Buitelaar, E. Bøen, et al.

    The human thalamus is an integrative hub for multiple cortical and subcortical circuits involved in sensory processing and higher cognitive functions. Thalamic volume differences have been reported across multiple psychiatric and neurological disorders, but previous studies have typically relied on small samples, focused on one or a limited number of disorders, or investigated the thalamus as a whole without considering its functional subdivisions. In this multi-site study, we compared thalamic nuclei volumes across mild cognitive impairment (MCI), dementia (DEM), major depressive disorder, schizophrenia spectrum disorder (SCZ), clinical high risk for schizophrenia, bipolar spectrum disorder, autism spectrum disorder, attention-deficit/hyperactivity disorder, Parkinson's disease, multiple sclerosis (MS), and healthy controls (N > 8000). Using structural MRI, we segmented 25 bilateral thalamic nuclei, corresponding to six anatomical groups. Linear models revealed that anterior, medial and lateral regions of the thalamus were significantly smaller in several conditions, with largest effects observed for MCI, DEM, SCZ and MS. In contrast, the ventral and intralaminar groups were relatively normal. This pattern of effects largely corresponds to the canonical functional subdivision of the thalamus into higher-order and sensory regions. At the level of individual nuclei, the clinical conditions were associated with distinct patterns of alterations, while left and right lateral geniculate nuclei were implicated in six of the disorders, suggesting a possible relation with circadian and sleep disturbances. Together, the results highlight a role for the higher-order thalamus in common brain disorders and a differential involvement at the nuclei level, refining our understanding of thalamic pathology across common brain disorders.


  • Open Access

    Brain age trajectories and cognition after stroke in two longitudinal cohorts

    by Gisle Berg Helland, Håkon Ihle-Hansen, Anne Hege Aamodt, Esten H Leonardsen, Tobias Kaufmann, Brian Anthony B Enriquez, Mona K Beyer, Stein Andersson, Helle Stangeland, Hanne F Harbo, et al.

    Brain age is a promising neuroimaging biomarker, reflecting biological aging, but long-term trajectories and predictive value for cognitive outcomes post-stroke remains unclear. This study aimed to characterize brain aging trajectories over 8 years following a first-ever stroke and to evaluate the predictive value of brain age estimates for long-term cognitive outcomes. We analysed data from working-age (<65 years) ischaemic stroke patients with small- and medium-sized strokes (lesion volumes <70 ml), using two longitudinal stroke cohorts. T1-weighted MRI was acquired in the acute phase and at multiple time points up to 8 years post-stroke. Montreal cognitive assessment (MoCA) was assessed at follow-up sessions. Brain age was estimated using a state-of-the-art deep learning model. Brain-predicted age difference (Brain-PAD) was calculated as estimated brain age minus chronological age and corrected by regressing on age, age² and sex. Linear mixed-effects models examined Brain-PAD over multiple time points (whole-brain, ipsilesional and contralesional). Normalized brain volume was derived from FreeSurfer and included in the whole-brain analysis. Linear regression models evaluated whether brain age was associated with cognitive performance (MoCA) at long-term follow-up. We included 120 patients [n = 50 (42%) female, mean ± SD age at discharge was 54.9 ± 9 and National Institutes of Health Stroke Scale was 3.7 ± 6.4], with a mean follow-up of 3.4 ± 2.5 years. The mean MoCA score at follow-up was 24.7 ± 3.7. Brain-PAD increased significantly over time in the whole-brain analysis (β = 0.6/year, P < 0.01), indicating 60% acceleration in brain aging after stroke, with the association remaining significant after adjusting for normalized brain volume (β = 0.5/year, P < 0.01). Accelerated brain aging was observed in the ipsilesional hemisphere (β = 0.7/year, P < 0.01), but not the contralesional hemisphere (β = 0.3/year, P = 0.12). Higher brain age in the acute phase of stroke predicted lower MoCA scores at follow-up (β = −0.12, P < 0.05), whereas chronological age was not a significant predictor (P = 0.12). The association between brain age estimations and cognitive performance remained significant after adjusting for age, sex and education (β = −0.42, P < 0.01). In this longitudinal study, we found accelerated brain aging following stroke. Furthermore, brain age was associated with cognitive outcomes several years later, highlighting its potential as an early biomarker for long-term cognitive prognosis.


  • Open Access

    Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab

    by Einar August Høgestøl, Åge Winje Brustad, Elisabeth Gulowsen Celius, Martine Meling, Pål Berg-Hansen, Grete Birkeland Kro, Marton König, Ylva Schanke, Bente Halvorsen, David J Warren, et al.

    Background: In January 2024, all people with multiple sclerosis (pwMS) treated with natalizumab (NTZ) at Oslo University Hospital were switched from originator to biosimilar NTZ. We prospectively evaluated disease activity, safety, serum drug levels, immunogenicity and biomarkers. Methods: This observational study included 39 pwMS switching to biosimilar NTZ. Clinical relapses, MRI activity and side effects were recorded. NTZ levels and anti-drug antibodies (ADAb) by in-house assays; anti-John Cunningham virus (JCV) antibodies by Stratify (Biogen) and Immunowell (Sandoz) platforms; leucocytes and serum levels of neurofilament light chain (NfL) and glial fibrillar acidic protein (GFAP) were measured by Mesoscale platform. Results: Eleven pwMS (28%) reported new side effects, most commonly fatigue, headache and muscle pain. Mean NTZ levels were 15.1 mg/L before and 14.9 mg/L after switching (difference –0.3, 95% CI –1.4 to 0.8). ADAb was detected in one pwMS, unchanged after switch. The proportion of JCV-positive cases increased from 13% (Stratify) to 52% (Immunowell), leading four pwMS to discontinue NTZ. Leukocytes were stable after switch. Median NfL remained stable (45.3 vs 44.0 pg/mL; median difference –1.3, 95% CI –6.0 to 3.5), whereas GFAP decreased (23.0 vs 20.5 pg/mL; difference –2.5, 95% CI –4.7 to –0.3). Conclusions: Switching from originator to biosimilar NTZ was associated with stable disease activity. Drug levels, ADAb, leukocytes and NfL remained similar before and after switching, and GFAP decreased, of uncertain relevance. The marked rise in JCV-positivity on the Immunowell assay underscores the need for harmonisation of anti-JCV antibody testing.

  • Open Access

    Quantitative susceptibility mapping of paramagnetic rim lesions in early multiple sclerosis: A cross-sectional study of brain age and disability

    by Lars Skattebøl, Rigmor Lundby, Mathias H. Øverås, Piotr Sowa, Elisabeth G. Celius, Hanne F. Harbo, Wibeke Nordhøy, Einar A. Høgestøl, Gro O. Nygaard


  • Open Access

    Brain age in multiple sclerosis: a study with deep learning and traditional machine learning

    by Lars Skattebøl, Gro O Nygaard, Esten H Leonardsen, Tobias Kaufmann, Thomas Moridi, Leszek Stawiarz, Russel Ouellette, Benjamin V Ineichen, Daniel Ferreira, J Sebastian Muehlboeck, et al.

    ‘Brain age’ is a numerical estimate of the biological age of the brain and an overall effort to measure neurodegeneration, regardless of disease type. In multiple sclerosis, accelerated brain ageing has been linked to disability accrual. Artificial intelligence has emerged as a promising tool for the assessment and quantification of the impact of neurodegenerative diseases. Despite the existence of numerous AI models, there is a noticeable lack of comparative imaging data for traditional machine learning versus deep learning in conditions such as multiple sclerosis. A retrospective observational study was initiated to analyse clinical and MRI data (4584 MRIs) from various scanners in a large longitudinal cohort (n = 1516) of people with multiple sclerosis collected from two institutions (Karolinska Institute and Oslo University Hospital) using a uniform data post-processing pipeline. We conducted a comparative assessment of brain age using a deep learning simple fully convolutional network and a well-established traditional machine learning model. This study was primarily aimed to validate the deep learning brain age model in multiple sclerosis. The correlation between estimated brain age and chronological age was stronger for the deep learning estimates (r = 0.90, P < 0.001) than the traditional machine learning estimates (r = 0.75, P < 0.001). An increase in brain age was significantly associated with higher expanded disability status scale scores (traditional machine learning: t = 5.3, P < 0.001; deep learning: t = 3.7, P < 0.001) and longer disease duration (traditional machine learning: t = 6.5, P < 0.001; deep learning: t = 5.8, P < 0.001). No significant inter-model difference in clinical correlation or effect measure was found, but significant differences for traditional machine learning-derived brain age estimates were found between several scanners. Our study suggests that the deep learning-derived brain age is significantly associated with clinical disability, performed equally well to the traditional machine learning-derived brain age measures, and may counteract scanner variability.


  • Open Access

    A cross-sectional multicentre study of multishell diffusion MRI in multiple sclerosis

    by Einar A. Høgestøl, Daniel A. Rinker, Ivan Maximov, Piotr Sowa, Elisabeth G. Celius, Tuva R. Hope, Atle Bjørnerud, Fuaad M. Sofia, Eloy Martinez de Las Heras, Elisabeth Solana, et al.


  • Open Access

    Multimodal predictors of disability progression and processing speed decline in relapsing-remitting multiple sclerosis

    by Max Korbmacher, Ingrid Anne Lie, Kristin Wesnes, Eric Westman, Thomas Espeseth, Karsten Specht, Ole Andreas Andreassen, Lars Tjelta Westlye, Stig Wergeland, Kjell-Morten Myhr, et al.

    The underlying mechanisms for neurodegeneration in multiple sclerosis are complex and incompletely understood. Multivariate and multimodal investigations integrating demographic, clinical, multi-omics, and neuroimaging data provide opportunities for nuanced analyses, aimed to define disease progression markers. We used data from a 12-year longitudinal multicenter cohort of 88 people with multiple sclerosis, to test the predictive value of multi-omics, T 1 -weighted MRI (lesion count and volume, lesion-filled brain-predicted age), clinical examinations, self-reports on quality of life, demographics, and general health-related variables for future functional and cognitive disability. Systematic increases in Expanded Disability Status Scale (EDSS) scores were used to stratify a progressive disability group (PDG) from relatively stabile disability. A processing speed decline group (PSDG) was defined by a ≥20% decrease from the maximum (cognitive) Paced Auditory Serial Addition Test score. We used a multiverse approach to identify which baseline variables were most predictive for PDG and PSDG memberships, considering multiple analysis paths. Future disability (median area under the curve: mAUC=0.83±0.04, median Brier score: mBS=0.16±0.02) and the loss of processing speed (mAUC=0.89±0.05, mBS=0.10±0.03) could be successfully classified across models. Varibles significantly (median p-valuesPDG =7.44±4.07, p median =0.013, proportion of the OR’s directionality: PORSD=100%), lower baseline EDSS for each 1-unit (mOR PDG =0.25±0.11, p median =0.013, PORSD=100%), and counter-intuitively every year increase in baseline age (mOR PDG =1.12±0.04, p median =0.020, PORSD=100%), and lower vitamin A per 1 umol/L (mOR PDG =0.10±0.05, p median =0.016, PORSD=99.7%) and D levels per 1 nmol/L (mOR PDG =0.95±0.02, p median =0.025, PORSD=100%). Variables significantly predicting stable processing speed were receiving disease modifying treatment at 12-year follow-up (mOR PSDG =0.10±0.08, p median =0.013, PORSD=100%) and baseline PASAT score (mOR PSDG =0.86±0.03, p median =0.005, PORSD=99.73%). These findings were supported by an additional simulation study. Concordant with the literature, disease modifying treatments influence disability progression, as well as a higher EDSS and PASAT scores at measurement start. Experimental and counterintuitive findings on vitamin A and D levels require further validation. The large variability across models suggests a strong influence of analytic flexibility, such as the selection of covariates.